Clinical Trials Logo

Clinical Trial Summary

Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients according to the prescribing information.

AVAMYS is a registered trademark of the GSK group of companies.


Clinical Trial Description

n/a


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01001130
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date May 2010
Completion date May 2014

See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT01957202 - A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) Phase 2
Completed NCT01949051 - A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis Phase 2
Completed NCT01962467 - A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine Phase 1
Completed NCT01622283 - Pharmacokinetic Study of Levocetirizine Oral Solution Phase 1
Completed NCT02397915 - Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays Phase 4
Completed NCT01445262 - Drug Use Investigation for XYZAL® N/A
Completed NCT01916226 - A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Phase 4
Completed NCT00109486 - Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray Phase 3